Beth-Ann Lesnikoski, MD, FACS Director of the Breast Program

Beth-Ann Lesnikoski, MD, FACS is a Director of the Breast Program for Baptist Health in Jacksonville, FL

Areas of Expertise Include:

  • Multidisciplinary Breast Cancer Care
  • NEW: Online doctor visits
  • Breast Cancer
  • Cancer Genetics
  • Oncoplastic Breast Surgery
  • Geriatric Breast Care
  • Premenopausal Breast Cancer
  • Pregnancy Related Breast Cancer

About the Doctor

Beth-Ann Lesnikoski, MD, FACS, is a board-certified surgeon with extensive experience in the surgical and multidisciplinary management of breast cancer. She specializes in oncoplastic breast surgery and has expertise in many innovative approaches to breast cancer treatment. She is passionate about educating both patients and physicians in the most up-to-date approaches to breast care.

From the Doctor

I have loved living in Florida since I moved here in 2009. I feel most at peace when I am by the ocean. My husband and I enjoy boating, books and bicycling. I also do a bit of gardening and particularly enjoy growing orchids.

My philosophy of care is always patient centered. I believe a well-educated patient can make the best informed choices about their health care, so my staff and I spend lots of time educating patients during their visits. I am dedicated to providing the same level of excellent care to patients from all walks of life. I believe we caregivers are privileged to accompany and support patients on their health care journeys.

I also believe in the power of charity. I have been an active volunteer with the American Cancer Society for nearly two decades, and served as Chair of the Florida Division in 2016.

Titles

Specialties

General Surgeon
Board Certified: American Board of Surgery

Education & Training

Internship
The Swedish Hospital, Minneapolis, MN
Doctor of Medicine 1983 - 1987
Temple University, Philadelphia, PA
Residency 1987 - 1992
New England Deaconess Hospital, Boston, MA
Fellowship 1993 - 1993
Beth Israel Deaconess Medical Center, Boston, MA
Fellowship 1995 - 1996
Falkner Breast Center,

Hospital Affiliation

  • Baptist Medical Center Jacksonville

Legal Practice Name

Baptist MD Anderson Cancer Physicians

Publications

Publication Name

  • For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery.

    Sen S, Soulos PR, Herrin J, Roberts KB, Yu JB, Lesnikoski BA, Ross JS, Krumholz HM, Gross CP
    Surgery. 2014 May. 155(5)776-88 doi: 10.1016/j.surg.2013.12.009. Epub 2013 Dec 15
    PMID: 24787104 [PubMed - indexed for MEDLINE]

  • Patterns of use and short-term complications of breast brachytherapy in the national medicare population from 2008-2009.

    Presley CJ, Soulos PR, Herrin J, Roberts KB, Yu JB, Killelea B, Lesnikoski BA, Long JB, Gross CP
    J Clin Oncol. 2012 Dec 10. 30(35)4302-7 doi: 10.1200/JCO.2012.43.5297. Epub 2012 Oct 22
    PMID: 23091103 [PubMed - indexed for MEDLINE]

  • Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.

    Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ
    Breast Cancer Res Treat. 2010 Jan. 119(1)137-44 doi: 10.1007/s10549-009-0507-x.
    PMID: 19728082 [PubMed - indexed for MEDLINE]

  • Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?

    Murphy CD, Jones JL, Javid SH, Michaelson JS, Nolan ME, Lipsitz SR, Specht MC, Lesnikoski BA, Hughes KS, Gadd MA, Smith BL
    Am J Surg. 2008 Oct. 196(4)566-8 doi: 10.1016/j.amjsurg.2008.06.011. Epub 2008 Aug 29
    PMID: 18760400 [PubMed - indexed for MEDLINE]

  • Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ.

    Dominguez FJ, Golshan M, Black DM, Hughes KS, Gadd MA, Christian R, Lesnikoski BA, Specht M, Michaelson J, Smith BL
    Ann Surg Oncol. 2008 Jan. 15(1)268-73. Epub 2007 Sep 22
    PMID: 17891441 [PubMed - indexed for MEDLINE]

  • Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.

    Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP
    Clin Cancer Res. 2007 Feb 15. 13(4)1198-207.
    PMID: 17317830 [PubMed - indexed for MEDLINE]

  • Sentinel lymph node biopsy for occult breast cancer detected during breast reduction surgery.

    Golshan M, Lesnikoski BA, Lester S
    Am Surg. 2006 May. 72(5)397-400.
    PMID: 16719192 [PubMed - indexed for MEDLINE]

  • A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important.

    Jones JL, Zabicki K, Christian RL, Gadd MA, Hughes KS, Lesnikoski BA, Rhei E, Specht MC, Dominguez FJ, Smith BL
    Am J Surg. 2005 Oct. 190(4)517-20.
    PMID: 16164912 [PubMed - indexed for MEDLINE]

  • Treatment of breast cancer during pregnancy.

    Burstein HJ, Partridge AH, Lesnikoski BA
    Expert Opin Pharmacother. 2002 Apr. 3(4)423-8.
    PMID: 11934346 [PubMed - indexed for MEDLINE]

  • A comparison of ink-directed and traditional whole-cavity re-excision for breast lumpectomy specimens with positive margins.

    Gibson GR, Lesnikoski BA, Yoo J, Mott LA, Cady B, Barth RJ Jr
    Ann Surg Oncol. 2001 Oct. 8(9)693-704.
    PMID: 11597009 [PubMed - indexed for MEDLINE]

  • Xenogeneic endothelial cells activate human prothrombin.

    Siegel JB, Grey ST, Lesnikoski BA, Kopp CW, Soares M, Schulte am Esch J 2nd, Bach FH, Robson SC
    Transplantation. 1997 Sep 27. 64(6)888-96.
    PMID: 9326416 [PubMed - indexed for MEDLINE]

  • Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival.

    Candinas D, Lesnikoski BA, Robson SC, Miyatake T, Scesney SM, Marsh HC Jr, Ryan US, Dalmasso AP, Hancock WW, Bach FH
    Transplantation. 1996 Aug 15. 62(3)336-42.
    PMID: 8779679 [PubMed - indexed for MEDLINE]

  • Inhibition of platelet integrin GPIIbIIIa prolongs survival of discordant cardiac xenografts.

    Candinas D, Lesnikoski BA, Hancock WW, Otsu I, Koyamada N, Dalmasso AP, Robson SC, Bach FH
    Transplantation. 1996 Jul 15. 62(1)1-5.
    PMID: 8693522 [PubMed - indexed for MEDLINE]

  • Inhibition of platelet GPIIbIIIa prolongs survival of discordant cardiac xenografts.

    Lesnikoski BA, Candinas D, Hancock WW, Otsu I, Siegel J, Bach FH, Robson SC
    Transplant Proc. 1996 Apr. 28(2)703.
    PMID: 8623355 [PubMed - indexed for MEDLINE]

  • Soluble complement receptor type 1 and cobra venom factor in discordant xenotransplantation.

    Candinas D, Lesnikoski BA, Robson SC, Scesney SM, Otsu I, Myiatake T, Marsh HC Jr, Ryan US, Hancock WW, Bach FH
    Transplant Proc. 1996 Apr. 28(2)581.
    PMID: 8623282 [PubMed - indexed for MEDLINE]

  • Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection.

    Robson SC, Young VK, Cook NS, Metternich R, Kasper-Konig W, Lesnikoski BA, Pierson RN 3rd, Hancock WW, Candinas D, White DJ, Bach FH
    Transplantation. 1996 Mar 27. 61(6)862-8.
    PMID: 8623150 [PubMed - indexed for MEDLINE]

  • Endothelial and host mononuclear cell activation and cytokine expression during rejection of pig-to-baboon discordant xenografts.

    Lesnikoski BA, Shaffer DA, Van der Werf WJ, Dalmasso AP, Soares MP, Latinne D, Bazin H, Hancock WW, Bach FH
    Transplant Proc. 1995 Feb. 27(1)290-1.
    PMID: 7879007 [PubMed - indexed for MEDLINE]